<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912444</url>
  </required_header>
  <id_info>
    <org_study_id>NATT</org_study_id>
    <nct_id>NCT00912444</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer</brief_title>
  <acronym>NATT</acronym>
  <official_title>A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pathological complete response (pCR) rate in
      triple-negative or Her2 positive breast cancer patients treated with neoadjuvant docetaxel,
      anthracycline and cyclophosphamide (TAC) or docetaxel and cyclophosphamide (TC) regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the leading cause of cancer in women in China. Neoadjuvant chemotherapy for
      treatment of locally advanced breast cancer has become a standard therapy. Results from
      neoadjuvant trials have shown that pathological complete response (pCR) is an independent
      predictor of outcome. Docetaxel was introduced into clinical practice in the early 1990s and
      has demonstrated good activity in the adjuvant and metastatic settings. Both TC and TAC are
      effective regimens in the adjuvant setting. The most optimal regimen in the neoadjuvant
      treatment is however unknown. This is especially true in triple-negative or HER2 positive
      breast cancer. This study will evaluate the pCR rate of TAC and TC as neoadjuvant treatment
      for triple-negative or HER2 positive breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    TAC treatment was associated with better survial outcome compared with TC treatment, we
    terminated recruiting and waiting for longer follow up period.
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete remission (pCR) rate</measure>
    <time_frame>after 6 cycles of neoadjuvant therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival (DFS) and overall survival (OS)</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>after 6 cycles of neoadjuvant therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile</measure>
    <time_frame>during neoadjuvant therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breast conservation therapy (BCT) rate</measure>
    <time_frame>after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TAC Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TC Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>six cycles of neoadjuvant Docetaxel and Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide</intervention_name>
    <description>Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles</description>
    <arm_group_label>TAC Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, cyclophosphamide</intervention_name>
    <description>Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles</description>
    <arm_group_label>TC Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged ≥ 18 years and &lt; 70 years

          -  Karnofsky performance status (KPS) ≥ 70

          -  At least one measurable disease according to the RECIST. histologically confirmed
             invasive breast cancer (excluding inflammatory breast cancer), T2N1 or locally
             advanced breast cancer (T3-4N0-3 or T0-4N2-3)

          -  Biopsy specimens are available for ER, PgR and Her2 detection, patients should be with
             triple negative or Her2 positive breast cancer, Her2 positivity is defined as
             FISH/CISH Her2 positive or IHC Her2 3+, Triple-negative disease defined as negativity
             for ER, PgR and Her2

          -  Adequate bone marrow function: Neutrophil ≥ 1.5*109/L; Hb ≥ 100g/L; PLT ≥ 100*109/L

          -  An estimated life expectancy of at least 12 months

          -  Willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible
             for treatment and follow-up

          -  Women with potential child-bearing must have a negative pregnancy test (urine or
             serum) within 7 days of drug administration and agree to use an acceptable method of
             birth control to avoid pregnancy for the duration of the study

          -  Written informed consent according to the GCP

        Exclusion Criteria:

          -  Prior systemic or loco-regional treatment of breast cancer, including chemotherapy

          -  Metastatic breast cancer

          -  With a history of malignant tumor except uterine cervix cancer in situ or skin basal
             cell carcinoma

          -  Patients with medical conditions that indicate intolerant to neoadjuvant therapy and
             related treatment, including uncontrolled pulmonary disease, diabetes mellitis, severe
             infection, active peptic ulcer, coagulation disorder, connective tissue disease or
             myelo-suppressive disease

          -  inadequate liver function (bilirubin &gt; 1.0 times upper normal limit [UNL] and ALT
             and/or AST&gt; 1.5 UNL associated with alkaline phosphatase &gt; 2.5 UNL; inadequate renal
             function (creatinine &gt; 1.0 times UNL and in case of limit value, Creatinine clearance
             &lt; 60 ml/min)

          -  Contraindication for using dexamethasone

          -  History of congestive heart failure, uncontrolled or symptomatic angina pectoris,
             arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP &gt; 180
             mmHg or diastolic BP &gt; 100 mmHg)

          -  Has peripheral neuropathy ≥ grade 1

          -  Patient is pregnant or breast feeding

          -  Known severe hypersensitivity to any drugs in this study

          -  Treatment with any investigational drugs within 30 days before the beginning of study
             treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Maternal and Child Health Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou General Hospital of Guangzhou Military Area</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangyin People's Hospital</name>
      <address>
        <city>Jiangyin</city>
        <state>Jiangsu</state>
        <zip>214440</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affilliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wujiang First People's Hospital</name>
      <address>
        <city>Wujiang</city>
        <state>Jiangsu</state>
        <zip>215200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The third hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linyi People's Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Obstetrics and Gynecology Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the International Peace Maternity and Child health Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincical Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fisrt Affiliated Hospital of Medical College of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinkiang Uygur Autonomous Region Cancer Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yunnan Provincical Tumor Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650106</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital affiliated to Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Traditional Chinese Medical Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo First People's Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affilliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruian People's Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325208</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24292815</url>
    <description>published result link</description>
  </link>
  <reference>
    <citation>Yang L, Li LD, Chen YD, Parkin DM. [Time trends, estimates and projects for breast cancer incidence and mortality in China]. Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):438-40. Chinese.</citation>
    <PMID>17152490</PMID>
  </reference>
  <reference>
    <citation>Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7. Erratum in: J Clin Oncol. 2007 May 1;25(13):1819.</citation>
    <PMID>17135639</PMID>
  </reference>
  <reference>
    <citation>Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13.</citation>
    <PMID>15930421</PMID>
  </reference>
  <reference>
    <citation>Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15;11(16):5678-85.</citation>
    <PMID>16115903</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>November 19, 2016</last_update_submitted>
  <last_update_submitted_qc>November 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Anthracycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

